Search - tctmd.com

Displaying 121 - 134 of 134

Sort: Relevancy | Date

News Daily News

Physically Active Less Likely to Die After MI Than Sedentary Individuals

Michael O'Riordan

April 14, 2017

News Daily News

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

Michael O'Riordan

April 12, 2017

News Daily News

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Michael O'Riordan

March 08, 2017

News Daily News

HDL Function Improved With Olive Oil-Enriched Mediterranean Diet: PREDIMED Study

Michael O'Riordan

February 14, 2017

News Features

Be It Resolved: Lifestyle Changes for Patients Needing Cardiac Rehab May Be a Life or Death Matter

Michael O'Riordan

January 10, 2017

News Features

We Asked, You Answered: Exercise by the Numbers

Yael L. Maxwell

October 26, 2016

News Daily News

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Michael O'Riordan

August 12, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

Advertisement

Physically Active Less Likely to Die After MI Than Sedentary Individuals

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

HDL Function Improved With Olive Oil-Enriched Mediterranean Diet: PREDIMED Study

Be It Resolved: Lifestyle Changes for Patients Needing Cardiac Rehab May Be a Life or Death Matter

We Asked, You Answered: Exercise by the Numbers

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content